Serum Levels of Thioredoxin Are Associated with Stroke Risk, Severity, and Lesion Volumes
Molecular Neurobiology - 2014
Tóm tắt
Oxidative stress increases serum thioredoxin (TRX), a redox-regulating protein with antioxidant activity recognized as an oxidative stress marker. The aim of this study was to assess the clinical significance of serum TRX levels in Chinese patients with acute ischemic stroke (AIS). From January 1, 2012, to December 31, 2013, all patients with first-ever acute ischemic stroke were recruited to participate in the study. Serum levels of TRX were assayed with solid-phase sandwich enzyme-linked immunosorbent assay (ELISA), and the severity of stroke was evaluated with the National Institutes of Health Stroke Scale (NIHSS) score on admission. The results indicated that the median serum TRX levels were significantly (P < 0.0001) higher in stroke patients as compared to normal cases [15.03 ng/mL (interquartile range (IQR), 10.21–32.42) and 8.95 ng/mL (6.79–11.05), respectively]. We found the serum TRX reflected the disease severity of AIS. There was a significant positive association between serum TRX levels and NIHSS scores (r = 0.476, P < 0.0001). After adjusting for all other possible covariates, TRX remained as an independent marker of AIS with an adjusted OR of 1.245 (95 % confidence interval (CI), 1.164–1.352; P < 0.0001). Based on the receiver operating characteristic (ROC) curve, the optimal cutoff value of serum TRX levels as an indicator for auxiliary diagnosis of AIS was projected to be 11.0 ng/mL, which yielded a sensitivity of 80.3 % and a specificity of 73.7 %, with the area under the curve at 0.807 (95 % CI, 0.766–0.847). Further, in our study, we found that an increased risk of AIS was associated with serum TRX levels ≥11.0 ng/mL (adjusted OR 6.99; 95 % CI, 2.87–12.87) after adjusting for possible confounders. Our study demonstrated that serum TRX levels at admission were associated with stroke severity and lesion volumes. Elevated levels could be considered as a novel, independent diagnosis marker of AIS in a Chinese sample.
Từ khóa
Tài liệu tham khảo
Zhang ZG, Wang C, Wang J, Zhang Z, Yang YL, Gao L, Zhang XY, Chang T, Gao GD, Li LH (2014) Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke. Mol Neurobiol. doi:10.1007/s12035-014-8682-0
Allen CL, Bayraktutan U (2009) Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 4(6):461–470
Liu L, Wang D, Wong KS, Wang Y (2011) Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke 42(12):3651–3654
Li SY, Gao Y, Ma WN et al (2014) The relationship between serum lipoprotein (a) levels and ischemic stroke risk: a cohort study in the Chinese population. Inflammation 37:686–693
Alexandrova ML, Bochev PG (2005) Oxidative stress during the chronic phase after stroke. Free Radic Biol Med 39(3):297–316
Chauhan A, Chauhan V (2006) Oxidative stress in autism. Pathophysiology 13:171–181
Söğüt S, Zoroğlu SS, Özyurt H et al (2003) Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 331(1):111–117
Cherubini A, Ruggiero C, Polidori MC et al (2005) Potential markers of oxidative stress in stroke. Free Radic Biol Med 39(7):841–852
Danton GH, Dietrich WD (2003) Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 62(2):127–136
Drake C, Boutin H, Jones MS et al (2011) Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun 25(6):1113–1122
Jikimoto T, Nishikubo Y, Koshiba M et al (2002) Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 38(10):765–772
Nakamura H, De Rosa S, Roederer M, Anderson MT, Dubs JG, Yodoi J, Holmgren A, Herzenberg LA, Herzenberg LA (1996) Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 8:603–611
Taniguchi Y, Taniguchi-Ueda Y, Mori K, Yodoi J (1996) A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (TRX) gene. Nucl Acids Res 24:2746–2752
Nakamura H (2005) Thioredoxin and its related molecules: update 2005. Antioxid Redox Signal 7:823–828
Nakamura H, Nakamura K, Yodoi J (1997) Redox regulation of cellular activation. Annu Rev Immunol 15:351–369
Burke-Gaffney A, Callister ME, Nakamura H (2005) Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26:398–404
Zhang XY, Chen DC, Xiu MH et al (2013) Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr Res 143(2):301–306
Al-Gayyar MMH, Abdelsaid MA, Matragoon S et al (2011) Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity. Br J Pharmacol 164(1):170–180
Griffiths HR, Bennett SJ, Olofsson P et al (2014) Thioredoxin as a putative biomarker and candidate target in age-related immune decline. Biochem Soc Trans 42(4):922–927
Hatano S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54:541–553
Adams HP, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
Bamford J, Sandercock P, Dennis M et al (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521–1526
Brott T, Adams HP Jr, Olinger CP et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870
Sims JR, Gharai LR, Schaefer PW et al (2009) ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology 72:2104–2110
Polidori MC, Frei B, Cherubini A, Nelles G, Rordorf G, Keaney JF Jr, Schwamm L, Mecocci P, Koroshetz WJ, Beal MF (1998) Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic Biol Med 25:561–567
Erecińska M, Silver IA (2001) Tissue oxygen tension and brain sensitivity to hypoxia. Respir Physiol 128(3):263–276
Şeneş M, Kazan N, Coşkun Ö et al (2007) Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 44(1):43–47
Sánchez-Moreno C, Dashe JF, Scott T et al (2004) Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 35(1):163–168
El Kossi MMH, Zakhary MM (2000) Oxidative stress in the context of acute cerebrovascular stroke. Stroke 31(8):1889–1892
Polidori MC, Cherubini A, Stahl W, Senin U, Sies H, Mecocci P (2002) Plasma carotenoid and malondialdehyde levels in ischemic stroke patients: relationship to early outcome. Free Radic Res 36:265–268
Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S (2003) Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry 74:312–316
Fam SS, Morrow JD (2003) The isoprostanes: unique products of arachidonic acid oxidation—a review. Curr Med Chem 10:1723–1740
Kelly PJ, Morrow JD, Ning MM et al (2008) Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 39(1):100–104
Ozkul A, Akyol A, Yenisey C et al (2007) Oxidative stress in acute ischemic stroke. J Clin Neurosci 14(11):1062–1066
Chen H, Yoshioka H, Kim GS et al (2011) Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal 14(8):1505–1517
Carbonell T, Rama R (2007) Iron, oxidative stress and early neurological deterioration in ischemic stroke. Curr Med Chem 14(8):857–874
Nanetti L, Raffaelli F, Vignini A et al (2011) Oxidative stress in ischaemic stroke. Eur J Clin Investig 41(12):1318–1322
Luna JM, Moon YP, Liu KM et al (2014) High-sensitivity C-reactive protein and interleukin-6-dominant inflammation and ischemic stroke risk: the northern Manhattan study. Stroke 45(4):979–987
Maurice MM, Nakamura H, Gringhuis S et al (1999) Expression of the thioredoxin–thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 42:2430–2439
Ma YH, Su N, Chao XD et al (2012) Thioredoxin-1 attenuates post-ischemic neuronal apoptosis via reducing oxidative/nitrative stress. Neurochem Int 60(5):475–483
Ishrat T, Mohamed IN, Pillai B et al (2014) Thioredoxin-interacting protein: a novel target for neuroprotection in experimental thromboembolic stroke in mice. Mol Neurobiol. doi:10.1007/s12035-014-8766-x
Domínguez C, Delgado P, Vilches A et al (2010) Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke 41(4):653–660
Emsley HC, Smith CJ, Gavin CM et al (2003) An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 139(1–2):93–101
Saeed SA, Shad KF, Saleem T, Javed F, Khan MU (2007) Some new prospects in the understanding of the molecular basis of the pathogenesis of stroke. Exp Brain Res 182:1–10
Lipton SA (1999) Redox sensitivity of NMDA receptors. Methods Mol Biol 128:121–130
Chan PH (2005) Mitochondrial dysfunction and oxidative stress as determinants of cell death/survival in stroke. Ann NY Acad Sci 1042(1):203–209
Montecucco F, Lenglet S, Gayet-Ageron A et al (2010) Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 41(7):1394–1404
Hattori I, Takagi Y, Nakamura H, Nozaki K, Bai J, Kondo N, Sugino T, Nishimura M, Hashimoto N, Yodoi J (2004) Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid Redox Signal 6:81–87